
BioPhero A/S raises US$17m in Series A funding
New investor exFMC Ventures, as well as existing investors Syngenta Group Ventures and Novo Holdings also participated in the...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

Janssen to pledge COVID-19 vaccine to African Union
The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...

German antibodies in demand in USA
Initially, Seattle-based Just - Evotec Biologics will receive US$28.6m from the Defense Health Agency ("DHA") under a partnership announced...

EMA starts rolling review for Sputnik V vaccine
The EU applicant for Gam-COVID-Vac is R-Pharm Germany GmbH. The CHMP’s decision to start the rolling review is based on results from laboratory...

Rentschler Biopharma to produce 100m doses of CureVac vaccine
Rentschler Biopharma SE is preparing large scale cGMP production and formulation of Curevac’s mRNA vaccine CVnCoV. Under a contract, signed in...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...